Form 13-F position report

REVANCE THERAPEUTICS INC

Reported by MORGAN STANLEY

Company profile Manager portfolio Source filing
RVNC CUSIP 761330109 Manager CIK 0000895421
Latest reported change

Reported 798,796 shares, up 116,167 (17.0%) from the prior quarter.

Reported value -20.0%; share count 17.0% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q4 2022
Shares 798,796 Quarter-end amount reported
Reported value $14,745,773 Fair value at quarter end
Consecutive quarters held 36 Through Q4 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Manager history

Quarterly position history

How this manager's reported quarter-end position changed over time.

15 quarters
Quarter Activity Shares Change % of reported 13F Reported value Filed
Q1 2025 Reduced 0 -893,686 (-100.0%) 0 $0 2025-05-15
Q4 2024 Added 893,686 +26,559 (3.1%) < 0.01% $2,716,806 2025-02-14
Q3 2024 Reduced 867,127 -109,968 (-11.3%) < 0.01% $4,500,393 2024-11-14
Q2 2024 Reduced 977,095 -226,809 (-18.8%) < 0.01% $2,511,135 2024-08-14
Q1 2024 Added 1,203,904 +324,655 (36.9%) < 0.01% $5,923,213 2024-05-15
Q4 2023 Added 879,249 +277,054 (46.0%) < 0.01% $7,728,599 2024-02-13
Q3 2023 Reduced 602,195 -37,561 (-5.9%) < 0.01% $6,907,177 2023-11-15
Q2 2023 Reduced 639,756 -94,220 (-12.8%) < 0.01% $16,192,226 2023-08-14
Q1 2023 Reduced 733,976 -64,820 (-8.1%) < 0.01% $23,641,368 2023-05-15
Q4 2022 Added 798,796 +116,167 (17.0%) < 0.01% $14,745,773 2023-02-14
Q3 2022 Added 682,629 +179,545 (35.7%) < 0.01% $18,430,000 2022-11-14
Q2 2022 Added 503,084 +85,977 (20.6%) < 0.01% $6,953,000 2022-08-15
Q1 2022 Added 417,107 +48,020 (13.0%) < 0.01% $8,133,000 2022-05-13
Q4 2021 Added 369,087 +86,477 (30.6%) < 0.01% $6,023,000 2022-02-14
Q3 2021 Reduced 282,610 -8,091 (-2.8%) < 0.01% $7,873,000 2021-11-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history
Institutional context

Who else reported the position

217 managers reported REVANCE THERAPEUTICS INC for Q4 2022.

Manager Activity Shares Change % of reported 13F Reported value Tenure
Capital World Investors Added 9,480,156 +1,431,318 0.04% $175,003,680 19 qtrs
BlackRock Inc Added 7,073,863 +942,047 < 0.01% $130,583,512 35 qtrs
Palo Alto Investors LP Added 5,283,609 +878,570 8.32% $97,535,422 13 qtrs
JPMorgan Chase & Co Reduced 5,014,422 -436,076 0.01% $92,567,000 36 qtrs
Polar Capital Holdings Plc Added 4,848,633 +386,886 0.71% $89,505,765 9 qtrs
VANGUARD GROUP INC Added 4,496,316 +183,420 < 0.01% $83,001,994 36 qtrs
FRANKLIN RESOURCES INC Reduced 2,384,590 -1,428 0.02% $44,019,531 35 qtrs
STATE STREET CORPORATION Added 2,049,595 +433,142 < 0.01% $37,835,524 36 qtrs
JENNISON ASSOCIATES LLC Added 2,026,025 +953,790 0.04% $37,400,420 12 qtrs
FMR LLC Added 1,809,255 +60,265 < 0.01% $33,398,847 25 qtrs
A free account expands this comparison to 25 managers. Create free account
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
December 31, 2022
Filed
February 14, 2023
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
642,665
Shared
1,552
None
154,579

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.